Drugs / Unfractioned Heparin
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01555658 | Apr → Sep 2012 | coronary artery disorder | University of Roma La Sapienza | Unknown | No outcome recorded |
| Phase 3 | NCT00100308 | Jul 2005 → Jul 2007 | bacterial infectious disease, infectious disease with sepsis | Universidad de Antioquia | Completed | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT02181998 Comparator | Jul 2000 → Aug 2002 | myocardial infarction | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT02531165 Background | Sep 2015 → Feb 2018 | acute myocardial infarction | Centre Hospitalier Universitaire Vaudois | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Unfractioned Heparin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02531165 ↗ |
| Known as | UFH | “The three clinical trials for recombinant anticoagulants allowed the use of prophylactic treatment for venous thrombosis with a dose of unfractioned heparin (UFH) of up to...” NCT00100308 ↗1“to IV UFH (60 IU/kg intravenous bolus followed by boluses with target activated clotting time 200-250 s)” NCT01555658 ↗ |
| Route | Intravenous | “to IV UFH” NCT01555658 ↗ |